WEBVTT

1
00:00:00.150 --> 00:00:03.679
Rosa has confirmed kidney
disease, type two diabetes, and

2
00:00:03.691 --> 00:00:06.531
an A one C already at
her individualized goal.

3
00:00:06.698 --> 00:00:09.033
That glucose result does
not settle the question of

4
00:00:09.045 --> 00:00:11.127
kidney and cardiovascular protection.

5
00:00:11.434 --> 00:00:14.750
Compare therapies using the actual
population and clinical outcome

6
00:00:14.762 --> 00:00:17.977
studied. Consider an
appropriate S G L T two

7
00:00:17.989 --> 00:00:21.480
inhibitor, review blood pressure
treatment, and assess whether additional

8
00:00:21.616 --> 00:00:25.747
evidence-based therapy fits her kidney
function, potassium, other conditions,

9
00:00:25.840 --> 00:00:29.267
and preferences. A reduction
in urine albumin is useful

10
00:00:29.279 --> 00:00:32.083
information, but it is
not the same endpoint as

11
00:00:32.095 --> 00:00:34.882
fewer kidney failures or
cardiovascular events.

12
00:00:35.124 --> 00:00:39.497
Discuss benefits, adverse effects,
affordability, and monitoring together.

13
00:00:39.705 --> 00:00:42.722
The takeaway: treat the
person's organ risk, not only

14
00:00:42.734 --> 00:00:43.814
the glucose number.